Martin Prinz, CTO of Croma-Pharma, a family-owned Austrian aesthetic dermatology company, discusses the evolution of the company over the years and their specialist, ever-expanding portfolio. Additionally, he documents the role of training clinics in establishing a vertical business model and provides an overview of the company’s growing global reach, namely into China, Brazil and soon the US, bolstered by the soon-to-be-constructed 40 million EUR manufacturing plant that will quadruple the company’s production capacity.
What was the reasoning behind the company’s shift towards aesthetic dermatology?
"We aim to be one of the first companies to completely remove harmful toxins from our products and we plan to release our own Botox in 2020 to increase our profitability."
